Gilead Sciences, Inc. (GILD) To Go Ex-Dividend on December 13th

Gilead Sciences, Inc. (NASDAQ:GILD) declared a quarterly dividend on Thursday, October 25th, RTT News reports. Investors of record on Friday, December 14th will be paid a dividend of 0.57 per share by the biopharmaceutical company on Friday, December 28th. This represents a $2.28 annualized dividend and a yield of 3.35%. The ex-dividend date of this dividend is Thursday, December 13th.

Gilead Sciences has a dividend payout ratio of 34.8% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Gilead Sciences to earn $7.23 per share next year, which means the company should continue to be able to cover its $2.28 annual dividend with an expected future payout ratio of 31.5%.

Shares of GILD opened at $68.15 on Friday. Gilead Sciences has a 12-month low of $64.27 and a 12-month high of $89.54. The firm has a market cap of $90.80 billion, a P/E ratio of 7.96, a PEG ratio of -2.72 and a beta of 1.01. The company has a current ratio of 3.45, a quick ratio of 3.37 and a debt-to-equity ratio of 1.09.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.63 by $0.21. Gilead Sciences had a return on equity of 39.32% and a net margin of 7.12%. The firm had revenue of $5.60 billion for the quarter, compared to analysts’ expectations of $5.44 billion. During the same period last year, the business posted $2.27 earnings per share. As a group, analysts predict that Gilead Sciences will post 6.44 EPS for the current fiscal year.

In other news, Director John C. Martin sold 50,000 shares of the firm’s stock in a transaction on Monday, October 1st. The stock was sold at an average price of $78.04, for a total transaction of $3,902,000.00. Following the transaction, the director now directly owns 3,067,762 shares of the company’s stock, valued at $239,408,146.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 150,000 shares of company stock worth $10,939,500 over the last three months. Corporate insiders own 1.30% of the company’s stock.

GILD has been the topic of several analyst reports. Raymond James reaffirmed a “buy” rating on shares of Gilead Sciences in a research report on Thursday, November 1st. BidaskClub lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, October 24th. Piper Jaffray Companies lowered Gilead Sciences from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $85.00 to $75.00 in a research report on Friday, October 26th. Evercore ISI reaffirmed a “buy” rating on shares of Gilead Sciences in a research report on Wednesday, October 31st. Finally, Cantor Fitzgerald initiated coverage on Gilead Sciences in a research report on Monday, October 1st. They issued an “overweight” rating and a $87.00 target price on the stock. Eleven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $88.63.

COPYRIGHT VIOLATION WARNING: “Gilead Sciences, Inc. (GILD) To Go Ex-Dividend on December 13th” was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Featured Article: Find a Trading Strategy That Works

Dividend History for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with's FREE daily email newsletter.

Leave a Reply